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Glossary: CI = confidence interval; DBS = deep brain stimulation; HADS = Hospital 
Anxiety and Depression Scale; NMS = Non-motor symptoms; NMSS = NMSScale; 
NMSQ = NMSQuestionnaire; OR = odds ratio; PD = Parkinson’s disease; PDQ-8 = 8-
item PD Questionnaire; QoL = quality of life; SCOPA-A, -B, and -C = Scales for 
Outcomes in PD-motor examination, -activities of daily living, and -motor 
complications; STN = subthalamic nucleus 
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Abstract 
Background: Subthalamic nucleus (STN) deep brain stimulation (DBS) improves 
quality of life (QoL), motor, and non-motor symptoms (NMS) in advanced Parkinson’s 
disease (PD). However, considerable inter-individual variability has been observed 
for QoL outcome. 
Hypothesis: We hypothesized that demographic and preoperative NMS 
characteristics can predict postoperative QoL outcome. 
Methods: In this ongoing, prospective, multicenter study (Cologne, Manchester, 
London) including 88 patients, we collected the following scales preoperatively and 
on follow-up 6 months postoperatively: PDQuestionnaire-8 (PDQ-8), NMSScale 
(NMSS), NMSQuestionnaire (NMSQ), Scales for Outcomes in PD (SCOPA)-motor 
examination, -complications, and –activities of daily living, levodopa equivalent daily 
dose. We dichotomized patients into “QoL responders”/“non-responders” and 
screened for factors associated with QoL improvement with (1) Spearman-
correlations between baseline test scores and QoL improvement, (2) step-wise linear 
regressions with baseline test scores as independent and QoL improvement as 
dependent variables, (3) logistic regressions using aforementioned “responders/non-
responders” as dependent variable. 
Results: All outcomes improved significantly on follow-up. However, approximately 
44% of patients were categorized as “QoL non-responders”. Spearman-correlations, 
linear and logistic regression analyses were significant for NMSS and NMSQ but not 
for SCOPA-motor examination. Post-hoc, we identified specific NMS (flat moods, 
difficulties experiencing pleasure, pain, bladder voiding) as significant contributors to 
QoL outcome. 
Conclusions: Our results provide evidence that QoL improvement after STN-DBS 
depends on preoperative NMS characteristics. These findings are important in the 
advising and selection of individuals for DBS therapy. Future studies investigating 
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motor and non-motor PD clusters may enable stratifying QoL outcomes and help 
predict patients’ individual prospects of benefiting from DBS. 
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1. Introduction 
Subthalamic nucleus (STN) deep brain stimulation (DBS) is well established as a 
treatment option for advanced Parkinson’s disease (PD) improving motor symptoms 
[1], quality of life (QoL) [2] and non-motor symptoms (NMS) [3] on a group level. 
However, studies investigating outcomes on the subject level indicate that a 
considerable proportion of patients (between 43-49%) do not experience a relevant 
QoL improvement after STN-DBS [4, 5]. Data on the preoperative determinants QoL 
outcome are scarce and suggest a role of some motor aspects, such as long daily off 
time [4] or small levodopa challenge test response [6], as well as some 
neuropsychiatric factors, such as high apathy scores [7]. In the present study, we 
therefore conducted a comprehensive assessment of a wide range of non-motor and 
motor symptoms to explore predictors of beneficial QoL outcome after STN-DBS. We 
hypothesized that NMS can predict QoL outcome after DBS. 
 
2. Methods 
2.1. Study design 
In this ongoing, prospective, open-label, multicenter, international study (Cologne, 
London, Manchester) we examined patients with PD undergoing bilateral 
implantation of stimulation electrodes for STN-DBS in the DBS arm [3] of the EuroInf 
study at preoperative baseline and follow-up 6 months after surgery. Data from 35 
patients was included in a previous analysis published by our group on beneficial 
non-motor effects of STN-DBS in a large cohort of patients with PD [3]. 
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2.2. Ethical approval 
The study was carried out in accordance with the Declaration of Helsinki and 
approved by local ethics committees (Cologne, study no.: 12–145; German Clinical 
Trials Register: DRKS00006735; United Kingdom: NIHR portfolio (Clinical Research 
Network) number: 10084; National Research Ethics Service South East London REC 
3, 10/H0808/141). Patients gave written informed consent prior to study procedures. 
 
2.3. Patients 
All patients fulfilled British Brain Bank PD diagnosis criteria and DBS treatment 
criteria of the International PD and Movement Disorders Society [8]. According to 
clinical routine, an eligibility for DBS treatment required a sufficient levodopa test 
response (>30% improvement in the Unified Parkinson’s Disease Rating Scale-III) 
and an exclusion of clinically relevant cognitive impairments and psychiatric diseases 
in assessments by expert neuropsychologists and psychiatrists. 
 
2.4. Clinical assessment 
The following scales and questionnaires were assessed, as previously reported in the 
EuroInf study [3, 9, 10]. All scales were assessed preoperatively in a clinical MedON- 
and postoperatively in a clinical MedON/StimON-state. 
 
2.4.1 Quality of life 
QoL was assessed with the PD Questionnaire-8 (PDQ-8) [11] which has previously 
been used for patients with PD and STN-DBS [12, 13]. The PDQ-8 surveys the 
frequency of the following eight aspects of QoL: mobility, activities of daily living, 
emotional well-being, stigma, social support, cognition, communication, bodily 
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discomfort. The score ranges from 0 to 32 (no to maximum QoL impairment). PDQ 
data is presented as PDQ-8 Summary Index (PDQ-8 SI) [3, 12, 14]. 
 
2.4.2 Non-motor symptoms 
As the following non-motor scales assessed a time period of the previous four weeks 
before surveying, they reflected ON and OFF times. 
- The patient-based NMS Questionnaire (NMSQ) wich consists of 30 dichotomized 
items. NMSQ total score ranges from 0 (no NMS) to 30 (maximum NMS) [15]. 
- The clinician-administered NMS Scale (NMSS) consisting of 30 items covering 
nine domains of NMS: cardiovascular, sleep/fatigue, mood/apathy, perceptual 
problems/hallucinations, attention/memory, gastrointestinal tract, urinary, sexual 
function, and miscellaneous (including unexplained pain, taste/smell loss, weight 
changes, and sweating). NMSS total score ranges from 0 (no NMS) to 360 
(maximum NMS) [16]. 
- The Hospital Anxiety and Depression Scale (HADS) which consists of subscales 
testing anxiety and depression with seven items respectively. Subscales range 
from 0 (no anxiety/depression) to 21 (maximum anxiety/depression) [17]. 
 
2.4.3 Motor manifestation 
Motor examination, activities of daily living, and motor complications were assessed 
with Scales for Outcomes in Parkinson’s disease (SCOPA-A, -B, -C) which strongly 
correlate to the UPDRS and were derived from this scale [18]. The SCOPA was used 
for time economic reasons as its assessment time is approximately 4 times shorter 
than for the MDS-UPDRS [18-20]. 
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2.4.4 Levodopa-equivalent daily dose 
We computed the levodopa-equivalent daily dose according to the Tomlinson method 
[21]. 
 
2.5. Statistical analysis 
2.5.1 Changes of outcome parameters from baseline to follow-up 
Normal distribution was tested with the Shapiro-Wilk-test and outliers (>3 SD) were 
truncated to the next highest value. Test score changes from baseline to follow-up 
were detected with the Wilcoxon signed-rank test or paired t-test, when parameteric 
test criteria were fulfilled, and Bonferroni-correction for multiple comparisons. 
We explored the relationship between preoperative demographic and clinical features 
and QoL outcome in the following analyses. 
 
2.5.2 Relationship between baseline quality of life and changes of other 
outcomes 
a. Spearman-correlation analyses 
Spearman-correlations were computed between PDQ-8 SI change scores (PDQ-8 
SIbaseline – PDQ-8 SIfollow-up) and preoperative QoL (PDQ-8 SIbaseline), non-motor 
(NMSSbaseline, NMSQbaseline, HADSbaseline) and motor symptoms (SCOPA-motor 
examinationbaseline, -motor complicationsbaseline, -activities of daily livingbaseline), 
levodopa equivalent daily dosebaseline and demographic characteristics (age at 
intervention, disease duration, sex). Positive correlations reflect an association 
between higher baseline values of respective parameters and more PDQ-8 SI 
improvement. Due to the exploratory character of this analysis, significance 
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thresholds were not corrected for multiple comparisons. Results were accepted as 
significant at p<0.05. 
 
b. Predictor analysis 
Secondly, to identify preoperative predictors of postoperative QoL outcome, stepwise 
linear regressions were computed for candidate parameters identified in step one. In 
this step, candidate parameters from the correlation analyses (p<0.1) were included 
and multi-collinearity was checked (r>0.6). 
 
c. Dichotomization into “responders“/“non-responders“ and logistic 
regression analyses 
We divided the cohort into groups with and without clinically relevant QoL 
improvement (“responders”/“non-responders”) based on a designated threshold (≥½ 
SD of PDQ-8 SIbaseline) [3] which is a method that has been shown to reliably report 
clinically important differences [22]. We then calculated the proportion of 
“responders” based on this threshold. 
Exploratory logistic regression models with dichotomized QoL outcome as dependent 
and demographic factors and preoperative clinical parameters as independent 
variables were employed to confirm the utility of linear regression models to predict 
patients’ postoperative QoL changes. Additionally, Mann-Whitney U tests were 
computed to confirm Testbaseline differences between “responders”/“non-responders”. 
 
d. Exploratory analyses of NMSS item scores 
As we were interested in the relationship of QoL changes and specific aspects of 
NMS, all analyses were also carried out for NMSS item scores.  
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Due to an overlap between specific PDQ-8 and NMSS questions (see supplemental 
material section 1), additionally all calculations were confirmed with a modified PDQ 
in which respective items were omitted for calculations with corresponding NMSS 
items. 
 
3. Results 
Our study included 88 patients with PD (56 male) with mean age at intervention=61.2 
years (SD=8.1) and disease duration=10.5 years (SD=4.5). Here we present data 
from 30 patients from Manchester, 22 patients from London, and 36 patients from 
Cologne. The mean time to follow-up from surgery was 5.49 months (SD=0.86). 
 
3.1. Changes of outcome parameters from baseline to follow-up 
All outcome parameters significantly improved on follow-up (see table 1). As PDQ-8 
SI significantly improved, we explored changes of its domain scores: All domains, 
except ‘Cognition’, improved significantly (see figure 1 and supplemental table A). 
 
3.2. Relationship between baseline quality of life and changes of other 
outcomes 
a. Spearman-correlation analyses 
Table 2 shows the results of Spearman-correlations with preoperative test 
scores/demographic variables and PDQ-8 SI change scores. Foremost, a significant 
correlation was observed between baseline PDQ-8 SI score and postoperative PDQ-
8 SI improvement. Other significant correlations were weak (NMSS, NMSQ, and 
SCOPA-B). 
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b. Predictor analysis 
Using stepwise linear regression analyses including aforementioned preoperative 
demographic and clinical parameters, we identified predicting factors for the QoL 
outcome. The resulting model accounted for 42.6% (R²=0.446) of the variance in QoL 
change (F3,84=22.53, p<0.001). It included PDQ-8 SI (β=0.508, p<0.001), NMSS 
items 12 (“difficulties in experiencing pleasure”, β=0.268, p<0.005) and 23 (“high 
voiding frequency”, β=0.152, p<0.01). 
 
c. Dichotomization into “responders“/“non-responders“ and logistic 
regression analyses 
Based on the above mentioned cohort-based cut-off, the calculated threshold for a 
relevant PDQ-8 SI improvement was 8.22. In our cohort (87 patients with valid pre- 
and postoperative PDQ scores), 56.3% (n=49) of patients were identified as “QoL 
responders” and 43.7% (n=38) as “non-responders” and 16.1% (n=14) reported a 
relevant QoL worsening (deterioration≥½ SD of PDQ-8 SIbaseline). 
In logistic regressions exploring demographic parameters, we found that every 
additional year of age at intervention decreased the odds of postoperative QoL 
improvement by approximately 6% (odds ratio [OR]=0.944, confidence interval 
[CI]=0.891–0.999, p=0.047). Female sex was associated with higher odds of 
beneficiary postoperative QoL outcome (OR=2.626, CI=1.030 – 6.695, p=0.043). The 
odds of QoL improvement were increased for every additional point on the PDQ-8 
SIbaseline by approximately 5% (OR=1.051, CI=1.017–1.086, p=0.003), for every point 
on the NMSQ total scorebaseline by approximately 13% (OR=1.132, CI=1.027–1.248, 
p=0.012), and for every 10 points increase on the NMSS total scorebaseline by 16% 
(OR=1.016, CI=1.002–1.030, p=0.030). Mann-Whitney U tests confirmed significant 
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differences for the above mentioned parameters: PDQ-8 SIbaseline (p=0.007), NMSQ 
total scorebaseline (p=0.012), and NMSS total scorebaseline (p=0.037). 
 
d. Exploratory analyses of NMSS item scores 
Furthermore, specific NMSS items had a significant predicting potential: 
One extra point in NMSS item 11baseline (“flat moods”) raised the probability of a 
positive QoL outcome by approximately 74% (OR=1.739, CI=1.070–2.827, p=0.025), 
in item 27baseline (“pain”) by approximately 14% (OR=1.141, CI=1.010–1.288, 
p=0.034) and in item 29baseline (“weight changes”) by 27% (OR=1.270, CI=1.026–
1.572, p=0.028). 
In out cohort complete sets of predictor and outcome variables was available in 83 
patients. A fitted logistic regression model incorporating the aforementioned 
parameters: age at intervention, PDQ-8 SIbaseline, NMSQ total scorebaseline, and NMSS 
item 11baseline correctly classified 68.7% of patients into groups of “QoL 
responders”/”non-responders” (57/83, Nagelkerke’s R2=0.291) as opposed to only 
57,8% without predictors (48/83). In other words, the assessment of basic 
demographic features and clinical scales significantly increased the predictive 
accuracy of QoL response classification by approximately 10%. The receiver 
operating characteristic curve for the fitted logistic regression demonstrated the 
discriminatory power of the model (C-statistic=0.77, p<0.001, CI=0.668–0.873, see 
figure 2) [23] which reached 79.2% sensitivity and 62.9% specificity at the optimal 
trade-off point. 
For the most part, linear and logistic regression results were also confirmed in the 
Mann-Whitney U tests comparing baseline characteristics of “responders”/“non-
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responders”. “Responders” had significantly higher Testbaseline values for NMSS item 
11 (“flat moods”, p=0.005), item 12 (“difficulty experiencing pleasure”, p=0.001), item 
27 (“pain”, p=0.027), item 29 (“weight changes”, p=0.018). 
The results of additional analyses adressing the overlap of NMSS and PDQ-8 items 
are reported in the supplemental material A section 2. 
 
4. Discussion 
In this prospective, open-label, multicenter, international study including a cohort of 
88 patients with PD, STN-DBS significantly improved QoL, motor and non-motor 
outcomes as well as medication requirements on 6 months follow-up after surgery. 
However, we observed considerable inter-individual variance as only 56.3% of 
patients experienced a clinically relevant improvement of QoL (“QoL responders”). 
The remaining 43.7% of patients were to be classified as “QoL non-responders”, a 
rate well within the range of other cohorts (41–49%) [4, 5]. To address the unmet 
need of identifying factors which contribute to this high inter-individual variance, we 
evaluated the non-motor, motor, and demographic predictors of QoL outcome: 
 
4.1. Non-motor predictors of quality of life 
As a key finding of our study, we observed that preoperative non-motor aspects of 
PD, i.e. “difficulties in experiencing pleasure” and “high frequency of voiding”, were 
significant predictors of QoL outcome and together with preoperative QoL explained 
42.6% of the variance of postoperative QoL change. Furthermore, specific NMS (“flat 
moods”, “weight changes” and “pain”), global NMS burden, QoL at baseline, and 
demographic factors had a significant predictive value for the QoL outcome
.
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We explored not only preoperative QoL and motor symptoms but also NMS as 
potential predictors of QoL outcome because of the emerging concept of non-motor 
effects of DBS [24, 25]. This concept is based on evidence from comprehensive 
assessments with clinician-based and self-reported patient-based scales, e.g. for 
depressive symptoms [26], pain [27], sleep [28], gastrointestinal symptoms, 
excessive sweating, and perceptual problems/hallucinations [3], and also backed by 
a growing number of studies using laboratory-assisted objective measures for 
specific NMS, e.g. polysomnography for sleep [29], 13CO2 excretion for gastric 
emptying [30], urodynamic examination for urinary symptoms [31], caloric chambers 
for daily energy expenditure/weight changes [32], and sympathetic skin response for 
excessive sweating [33]. Furthermore, our previous work has provided evidence that 
patients with stronger postoperative improvement of NMS experience significantly 
more QoL improvement [3]. 
 
To understand the predictive potential of specific NMS for QoL outcomes in DBS 
several factors may be important: 
1. The strong link between QoL and NMS in PD is well known [34, 35]. As 
specific NMS are amenable to DBS their alleviation potentially also improves 
QoL. In this context the following mechanisms may play a role: Mood [36, 37] 
could be affected by a modulation of associative basal ganglia-thalamo-
cortical loops and autonomic symptoms like bladder control [31] and pain [27] 
by limbic circuitry. Furthermore, local effects may play a role, i.e. via the 
spread of current to brain brain regions next to the STN: The lateral 
hypothalamus could, e.g., be modulated which may result in weight changes 
[38]. 
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2. An improvement of sensory gaiting/processing: Previous studies have 
provided evidence that this PD-related pathopysiological mechanism is 
amenable to DBS but not necessarily to dopaminergic medication, e.g., in 
specific types of pain [39], bladder control [31] and auditory deficits [40]. 
Therefore, high preoperative severities of these NMS may be a surrogate 
marker for beneficial NMS outcome which may result in beneficial QoL 
outcome. 
3. Neuropsychiatric symptoms, such as depression and anxiety, are particularly 
important for DBS outcomes. A failure to improve in these symptoms can 
diminish subjective QoL outcome [7]. Consistent with findings from previous 
studies [5, 7], step-wise linear regressions showed that more improvement of  
“flat moods” and “difficulties experiencing pleasure” is an important 
determinant of more QoL improvement. One has to acknowledge that, unlike 
these NMSS items, HADS total scores did not predict QoL outcomes in our 
cohort. This discrepancy may result from the fact that these items flat moods 
and difficulties experiencing pleasure are more specific, whereas HADS total 
scores summarize a wider range of anxiety and depression symptoms. 
4. The reduction of non-motor and motor fluctuations due to the continuous 
effects of DBS may play an important role. Previous studies have provided 
evidence for an improvement of non-motor fluctuations of depressive mood 
and bladder urgency by DBS [41]. Furthermore, weight changes may stabilize 
in a subset of patients as a reduction of, e.g., dykinesia, rigidity and tremor 
resulting from motor fluctuations may alleviate excessive energy expenditure 
[42]. We found a predictive potential for QoL improvement in all these 
symptoms. 
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4.2. Predictive value of preoperative quality of life, motor and demographic 
parameters 
4.2.1 Preoperative quality of life 
In line with previous results [5, 43], we found that higher preoperative QoL 
impairment is a significant predictor of more postoperative QoL improvement. As 
regards the relationship between preoperative PDQ scores and postoperative PDQ 
outcomes our result of an OR=1.05 remarkably resembles results of the Cleveland 
Clinic cohort (same OR=1.05). In line with previous studies, we observed no 
improvement of the cognition domain [2, 5]. The confirmation of these results in an 
independent cohort emphasizes the validity of our results and the high test-retest 
validity of the PDQ [5].  
 
4.2.2 Preoperative motor manifestation 
In line with previously published studies in other cohorts [4, 5], we observed no 
significant predictive value of motor examination scores in our cohort. While there 
were negative results in previous studies regarding a relationship between 
preoperative UPDRS-III and postoperative QoL outcome, there was, however, 
evidence for a relationship with the response to dopaminergic medication, either 
directly (preoperative improvement in the levodopa challenge test) or indirectly 
(preoperative daily cumulative off time). We did not investigate levodopa response as 
all patients included in our study were required to fulfill the criterion of >30%  
UPDRS-III improvement in the levodopa test to be eligible for DBS surgery. 
Consequently, there is lack of patients with little improvement in the levodopa test 
and our cohort size was not powered for an analysis of the relationship between 
levodopa response and QoL outcome after STN-DBS. In fact, a retrospective study 
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by Floden et al. with a comparable cohort size (85 patients) provided no evidence for 
this relationship and the authors discussed the above mentioned statistical limitations 
[5]. 
 
4.2.3 Demographic factors 
Our results show that higher age at baseline decreases the odds of a beneficiary 
QoL outcome in patients undergoing STN-DBS. Studies investigating QoL outcomes 
in DBS have found that age per se may not be a key determinant of QoL, however, it 
may serve as a surrogate for age-related frailty and co-morbidities which in turn may 
influence QoL [44]. As regards gender differences, our results are in line with 
previous studies which have provided evidence for a significantly better QoL outcome 
in female patients undergoing DBS which may result from more subjective 
improvement of functional autonomy in women than in men [45]. 
 
4.3. Limitations 
There are a number of limitations of this study. 
As a prospective DBS registry study this was not a randomized or double-blinded 
study with a best medical treatment control group. However, as a prospective study 
reliability of data is likely to be better than in retrospective studies and its multicenter 
design is likely to reduce the potential bias of a single-center design. One has to 
acknowledge selection bias due to several factors: As per clinical routine patients 
with dementia or severe depression were not eligible for DBS. Additionally, only 
patients with motor complications and/or medication-refractory tremor underwent 
DBS surgery. Consequently, patients with very severe NMS are likely to be 
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underrepresented in our study which implies limitations for the analysis of NMS 
predictors of QoL. 
Regarding the statistical analysis, the choice of a cut-off value for the classification 
into “responders”/“non-responders” is a crucial point. Previous studies have 
employed the same method to derive a cohort-specific cut-off value (≥½ SD of PDQ-
8 SIbaseline) [3, 22]. The calculated cut-off=8.22 in our cohort was similar to a general 
PD population in which the reliable change index resulted in a cut-off=7.0 on the 
PDQ-39 SI (10.9 on the PDQ-39 total score) [4]. As the reliable change index is 
considered to be a conservative method for the calculation of clinically important 
difference in QoL [4] and our calculated threshold was comparable, we too applied a 
conservative cut-off for all logistic regression analyses. 
As explained in the supplemental material A section 1, there is a considerable 
overlap between the contents of questions of the PDQ and NMSS which may cause 
false postive results for the predictor analysis. To minimize this confounding effect, 
we additionally carried out all analyses with a modified PDQ score in which 
corresponding PDQ items were left out when respective NMSS items were tested 
and reincluded for analyses with all other NMSS items. The analyses with this 
modified PDQ by large confirmed the original results with the unmodified PDQ-8 
which increases the reliability of the results (see supplemental material A section 2.1 
and 2.2). As regards the motor scales used in the present study, SCOPA scores may 
offer limited comparability with (MDS)-UPDRS scores assessed in other studies. 
However, like the MDS-UPDRS the SCOPA is a reliable and valid instrument, the 
assessment of the SCOPA is approximately four times shorter making the scale more 
time-efficient, and conversion formulae between these scales are available [18-20]. 
Although the current work includes one of the biggest cohort sizes in studies of its 
kind (n=88), increased cohort sizes are required to employ more sophisticated 
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analyses, such as clustering and a stratification of outcomes. Additionally, 
assessments of further symptoms, such as impulsivity and apathy, could add value to 
predictive models [7]. Furthermore, from our relatively short follow-up, we cannot 
predict which factors contribute to long-term QoL improvement, in particular, as in 
some patients a relatively long time may be required to find stable effective 
stimulation parameters or to recover from medication withdrawal. A longer follow-up 
including neuropsychological and non-dopaminergic NMS as well as axial motor 
symptoms, such as falls, is required to address the long-term QoL outcome [46, 47]. 
The non-motor scales employed in this study survey NMS over a time period of four 
weeks prior to assessment summarizing ON and OFF times and therefore are not 
feasible to study the microstructure of non-motor fluctuations. An investigation of non-
motor OFF times and fluctuations may help to understand the impact of NMS on QoL 
and to address this issue further studies are needed including non-motor patient 
diaries. 
 
4.4. Conclusion 
The novel findings of this study regarding the predictive value of global and specific 
NMS for QoL outcome emphasize the importance of a holistic assessment of patients 
prior to surgery. Future studies investigating preoperative motor and non-motor PD 
profiles, e.g., with clustering methods, may enable a more precise assessment of 
patients’ expected postoperative QoL improvement. The overall aim is an 
individualized advising and better selection of patients for DBS therapy.  
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Table 1 – Baseline and follow-up characteristics 
 
Baseline Follow-up 
p 
n mean SD n mean SD 
PDQ-8 SI * 88 34.5 16.4 87 23.8 14.4 <0.001 
NMSS-T * 86 65.2 34.8 87 45.7 27.5 <0.001 
NMSQ-T * 85 11.0 4.9 83 8.1 3.9 <0.001 
HADS * 84 11.3 6.1 83 9.0 5.4 <0.001 
SCOPA-A * 86 7.8 3.8 83 5.6 2.9 <0.001 
SCOPA-B * 87 12.7 6.0 86 8.6 4.7 <0.001 
SCOPA-C * 86 5.4 3.0 87 3.0 2.8 <0.001 
LEDD * 88 1142.3 512.0 86 636.7 358.1 <0.001 
 
Abbreviations: HADS = Hospital Anxiety and Depression Scale; LEDD = Levodopa 
equivalent daily dose; NMSS-T = Non-motor Symptom Scale total score; NMSQ = Non-motor 
Symptoms Questionnaire; PDQ-8 SI = Parkinson's Disease Questionnaire-8 items Summary 
Index; SCOPA-A, -B, and -C = Short Outcomes of Parkinson's Disease-motor examination,  
-activities of daily living, and -motor complications 
All scales were assessed in preoperative MedON and postoperative MedON/StimON. 
The Bonferroni-correction was employed to correct for type I errors. 
* All outcome parameters improved significantly from baseline to follow-up. 
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Table 2 – Spearman-correlations between all preoperative scores or 
demographic variables and postoperative change scores of quality of life 
 
Spearman correlation 
PDQ-8 SI change score 
n rho p 
Age 87 -0.191 0.076 
Sex + 87 0.150 0.166 
Disease duration 87 -0.006 0.959 
PDQ-8 SI * 87 0.443 <0.001 
NMSS-T * 85 0.269 0.013 
NMSQ-T * 84 0.253 0.020 
HADS 83 0.131 0.239 
SCOPA-A 86 0.080 0.464 
SCOPA-B * 85 0.227 0.037 
SCOPA-C 85 0.059 0.591 
LEDD 87 -0.041 0.704 
 
Abbreviations: HADS = Hospital Anxiety and Depression Scale; LEDD = Levodopa 
equivalent daily dose; NMSS-T = Non-motor Symptom Scale total score; NMSQ = Non-motor 
Symptoms Questionnaire; PDQ-8 SI = Parkinson's Disease Questionnaire-8 items Summary 
Index; SCOPA-A, -B, and -C = Short Outcomes of Parkinson's Disease-motor examination,  
-activities of daily living, and -motor complications 
All scales were assessed in preoperative MedON and postoperative MedON/StimON. 
* Significant correlations between Testbaseline or demographic variable and PDQ-8 SI change 
scores 
+ Rank-biserial correlation 
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Figure 1 – PDQ-8 domain scores 
 
Figure 1 - A Parkinson’s disease-specific patient-based self-reported score (PDQ-8) 
was employed to assess quality of life at preoperative baseline (blue) and follow-up 6 
months after surgery (green). Data is presented as Summary Index (=percentage of 
maximum scores). Mean values of all domains improved from baseline to follow-up. 
Improvements of all domains were significant (black stars), except for the “Cognition” 
domain. Black bars illustrate standard deviations. ADL = Activities of daily living; 
Discomfort = Bodily discomfort; Emotions = Emotional well-being; PDQ-8 = 
Parkinson’s Disease Questionnaire (8-items version); Social = Social support. 
} } } } } } * * * * * * * } 
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Figure 2 – Regression classification accuracy 
 
 
Figure 2 – The receiver operating characteristic curve (blue) illustrates the 
classification accuracy of the fitted logistic regression model (dependent variable: 
PDQ-8 SI “responder”/”non-responder”, independent variables: age at intervention, 
PDQ-8 SIbaseline, NMSQ total scorebaseline, NMSS items 11baseline). The discriminatory 
power of the test with these parameters is demonstrated by C-statistic=0.77. The 
diagonal line (green) represents chance classification accuracy. The cross of black 
reference lines indicates the optimal trade-off point in which the model reached 
79.2% sensitivity and 62.9% specificity. 
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